Table 1

SIR for cancer of patients diagnosed with FAP from 1997 to 2010

MenWomenAll
OSIR95% CIOSIR95% CIOSIR95% CI
Cancer site             
 Colon 0.47 0.00 2.68 2.20 0.21 8.09 0.98 0.19 2.91 
 Rectum 1.47 0.14 5.40    1.13 0.11 4.15 
 Breast    0.54 0.05 1.99 0.54 0.05 1.97 
 Endometrium    2.27 0.21 8.33 2.27 0.21 8.33 
 Prostate 0.54 0.21 1.12    0.54 0.21 1.12 
Non-Hodgkin lymphoma 4.13 1.30 9.72 7.81 1.47 23.11 5.02 2.14 9.94 
 Diffuse large B cell 3.06 0.00 17.57 12.10 1.14 44.50 6.10 1.15 18.06 
 Others 5.78 1.50 14.94 7.18 0.00 41.18 7.70 2.43 18.10 
Leukemia    7.97 0.75 29.32 1.66 0.16 6.11 
All 19 0.59 0.36 0.93 11 0.92 0.46 1.65 30 0.68 0.46 0.98 
MenWomenAll
OSIR95% CIOSIR95% CIOSIR95% CI
Cancer site             
 Colon 0.47 0.00 2.68 2.20 0.21 8.09 0.98 0.19 2.91 
 Rectum 1.47 0.14 5.40    1.13 0.11 4.15 
 Breast    0.54 0.05 1.99 0.54 0.05 1.97 
 Endometrium    2.27 0.21 8.33 2.27 0.21 8.33 
 Prostate 0.54 0.21 1.12    0.54 0.21 1.12 
Non-Hodgkin lymphoma 4.13 1.30 9.72 7.81 1.47 23.11 5.02 2.14 9.94 
 Diffuse large B cell 3.06 0.00 17.57 12.10 1.14 44.50 6.10 1.15 18.06 
 Others 5.78 1.50 14.94 7.18 0.00 41.18 7.70 2.43 18.10 
Leukemia    7.97 0.75 29.32 1.66 0.16 6.11 
All 19 0.59 0.36 0.93 11 0.92 0.46 1.65 30 0.68 0.46 0.98 

The reference population was from the 2 endemic northernmost provinces (Norrbotten and Vesterbotten, Sweden). SIR was standardized for age and gender.

Bold type indicates 95% confidence interval, but does not include 1.00.

O, observed number of cases; CI, confidence interval.

or Create an Account

Close Modal
Close Modal